Trials / Unknown
UnknownNCT01752205
Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma
A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and effectiveness of erlotinib and chemoradiotherapy in patients with unresectable esophageal or gastro-esophageal squamous cancer .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel | 45mg/m2/w,total 6 weeks |
| DRUG | Erlotinib | 150mg/d,days 1-42,total 6 weeks |
| RADIATION | Radiation therapy |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2014-05-01
- Completion
- 2014-11-01
- First posted
- 2012-12-19
- Last updated
- 2012-12-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01752205. Inclusion in this directory is not an endorsement.